Plain-English translation of NCT04920968 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a newer antibody medication called works better than the standard antibody treatment, , when combined with chemotherapy for newly diagnosed acute lymphoblastic leukemia (a blood cancer). Both medications are designed to target and destroy cancer cells, but researchers want to know if the newer one offers any advantage in fighting this disease and whether it's as safe or safer to use.
has been used for many years in treating this type of leukemia, but doctors believe a newer medication might be even more effective or have fewer side effects. This trial will help determine whether switching to the new treatment is worth it for patients with this diagnosis.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the standard treatment or the newer treatment, both given alongside chemotherapy at the same time points. You will be closely monitored throughout your treatment with regular visits for blood tests, scans, and check-ins to track how well the medication is working and watch for any side effects. The trial will involve 124 patients total across multiple hospitals, with 62 patients receiving each medication.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Poland